Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Arvinas Inc (NQ: ARVN )

24.96 +0.48 (+1.96%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 449,320
Open 24.71
Bid (Size) 24.11 (1)
Ask (Size) 25.73 (1)
Prev. Close 24.48
Today's Range 24.57 - 25.16
52wk Range 13.57 - 53.08
Shares Outstanding 68,600,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Critical Insights From Arvinas Analyst Ratings: What You Need To Know
Via Benzinga
Arvinas to Participate in Upcoming Investor Conferences
From Arvinas Inc.
Via GlobeNewswire

Performance

YTD
-39.86%
-39.86%
1 Month
+0.04%
+0.04%
3 Month
-2.80%
-2.80%
6 Month
-33.71%
-33.71%
1 Year
+30.75%
+30.75%

More News

Read More
The Latest Analyst Ratings For Arvinas
Via Benzinga
ARVN Stock Earnings: Arvinas Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Arvinas Reports Second Quarter 2024 Financial Results and Provides Corporate Update
From Arvinas Inc.
Via GlobeNewswire
Analyst Ratings For Arvinas
Via Benzinga
HOOKIPA Pharma Announces Leadership Changes to Intensify Focus on HB-200
From HOOKIPA Pharma Inc.
Via GlobeNewswire
Biotech Arvinas Stock Earns 82 RS Rating
Via Investor's Business Daily
Why Charles Schwab Shares Are Trading Lower By Over 7%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
UnitedHealth Posts Better-Than-Expected Earnings, Joins AngioDynamics, Bank of America And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Arvinas Appoints Andrew Saik as Chief Financial Officer and Treasurer
From Arvinas Inc.
Via GlobeNewswire
Arvinas Announces Presentations for Two of its PROTAC® Investigational Programs Targeting BCL6 and LRRK2
From Arvinas Inc.
Via GlobeNewswire
Arvinas Announces Promotions of Ian Taylor, Ph.D. to President of Research and Development and Angela Cacace, Ph.D. to Chief Scientific Officer
From Arvinas Inc.
Via GlobeNewswire
These 3 Clinical-Stage Biotech Stocks Can Offer Exponential Gains
Via Talk Markets
Arvinas to Participate in Upcoming Investor Conferences
From Arvinas Inc.
Via GlobeNewswire
Arvinas Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Congress
From Arvinas Inc.
Via GlobeNewswire
Walmart Posts Upbeat Earnings, Joins Canada Goose, Lightspeed Commerce And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®)
From Arvinas Inc.
Via GlobeNewswire
NEXTracker Posts Upbeat Earnings, Joins monday.com, Nu Holdings And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress
From Arvinas Inc.
Via GlobeNewswire
ARVN Stock Earnings: Arvinas Beats EPS, Misses Revenue for Q1 2024
Via InvestorPlace
Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update
From Arvinas Inc.
Via GlobeNewswire
Arvinas to Present at Upcoming Investor Conferences
From Arvinas Inc.
Via GlobeNewswire
Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer
From Arvinas Inc.
Via GlobeNewswire
Biotech Stocks Heat As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options
Via Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.